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ABSTRACT
This prospective study evaluated Raman spectroscopy for the identiﬁcation of clinically relevant Candida
spp. in peritonitis patients. A Raman database was developed by measuring spectra from 93 reference
strains belonging to ten different Candida spp. Clinical samples were obtained from the surgical
department and intensive care unit of a tertiary university hospital. In total, 88 peritoneal specimens
from 45 patients with primary, secondary or tertiary peritonitis were included. Specimens were cultured
initially on a selective Sabouraud medium that contained gentamicin to suppress bacterial growth. For
conventional identiﬁcation, a chromogenic medium was used for presumptive identiﬁcation, followed
by use of the Vitek 2 system for deﬁnitive identiﬁcation (requiring a total time of 48–96 h). Raman
measurements were taken on overnight cultures from Sabouraud–gentamicin medium. Thirty-one
samples were positive for Candida by culture. Using multivariate statistical analyses, a prediction
accuracy of 90% was obtained for Raman spectroscopy, which appears to offer an accurate and rapid
(12–24 h) alternative for the identiﬁcation of Candida spp. in peritonitis patients. The reduced turn-
around time is of great clinical importance for the treatment of critically ill patients with invasive
candidiasis in intensive care units.
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INTRODUCTION
Candida spp. are often referred to as ‘emerging
pathogens’. Candida was considered originally to
be an insigniﬁcant, transient contaminant, but is
now recognised as a serious nosocomial pathogen
in non-neutropenic critically ill patients in inten-
sive care units (ICUs) [1–3]. The incidence of
Candida infections has risen signiﬁcantly during
recent decades, with the greatest increase occur-
ring in surgical services, and especially in patients
recovering from abdominal surgery [1,4–7]. The
morbidity and mortality associated with these
invasive Candida infections is striking, with the
median ICU stay increased by up to 30 days [8,9]
and mortality rates of 30–80% [10–13].
Several previous studies have assessed the
positive effect of early, systemic antifungal ther-
apy on the outcome of ICU patients with invasive
Candida infections, in terms of a decrease in both
morbidity and (attributable) mortality [3,4,11,14–
17]. As amphotericin B may have toxic side-
effects, ﬂuconazole is often the ﬁrst choice for
prophylactic or empirical antifungal therapy
[3,18,19]. However, two of the heralded problems
involved in using ﬂuconazole for prophylaxis are
the existence of ﬂuconazole-resistant non-albicans
Candida spp. [20], and the possible emergence of
ﬂuconazole resistance de novo through selective
pressure following prolonged use of azoles. Such
prolonged use may select for either less suscept-
ible non-albicans Candida spp., or a shift to
ﬂuconazole-resistant Candida albicans [21].
Accordingly, rapid identiﬁcation of signiﬁcant
isolates to the species, or even strain, level is
imperative for prompt initiation of appropriate
antifungal therapy, since susceptibility data for
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the isolate may not be available immediately.
Also, the adequacy of the initial, empirical treat-
ment has been proved to inﬂuence morbidity and
mortality. Changes in therapy following a delay
for culture results failed to improve outcome if
the initial regimen was inappropriate [22].
Current identiﬁcation techniques are, at best,
blunt instruments with limited sensitivity. A
convincing tool for the rapid diagnosis of invasive
candidiasis has yet to emerge [23]. However,
one possibility lies in the use of vibrational
spectroscopic techniques (Raman and infrared
spectroscopy), which yield spectra that are mole-
cule-speciﬁc. When applied to complex biological
samples, such as cells or tissues, the spectra are a
summation of the signal contributions of all
molecular species, and therefore reﬂect the overall
molecular composition of a sample. Such spectra
have been shown to be highly suitable for rapid
identiﬁcation of bacteria [24,25] and yeasts [26,27],
because they are reproducible and distinct for
different bacterial and fungal species. Previous
studies have indicated that the technique might
provide sufﬁcient resolving power to enable the
discrimination of microorganisms to the strain
level, and also to provide information regarding
susceptibility to antimicrobial or antifungal
agents [26,28]. Vibrational spectroscopy appears
to offer many advantages over current routine
methods for the identiﬁcation of Candida spp., in
that it requires minimal biomass and minimal
sample handling, but enables rapid, direct and
accurate analysis of samples, with the possibility
of automation. Rapid identiﬁcation of clinically
relevant microorganisms from solid culture med-
ium, based on confocal Ramanmicrospectroscopy,
has been reported recently. Reproducible Raman
spectra were obtained from microcolonies
10–100 lm in diameter after an incubation time
of only 6 h [29,30]. In view of these results, the
present study aimed to evaluate the feasibility,
accuracy and turn-around time of this technique
in a prospective clinical study for the identiﬁcation




A collection of 93 reference Candida strains, comprising ten
different Candida spp., was used. Strains were either obtained
from culture collections or were clinical isolates identiﬁed to
the species level by conventional identiﬁcation methods.
Strains were stored at ) 80C in brain–heart infusion broth
(Becton Dickinson, Franklin Lakes, NJ, USA) containing
glycerol 10% v ⁄v until use. Before measurements were made,
the strains were cultured on Sabouraud–gentamicin medium
(Merck, Darmstadt, Germany) for 12–24 h at 30C. Two
independent cultures of each reference strain were used to
generate Raman spectra.
Technical procedures of confocal Raman microspectroscopy
Raman spectra were generated as described previously [29,30].
Brieﬂy, with the CaF2 substrate placed under a microscope
(ﬁtted with an 80· near-infrared objective lens; MIR Plan
80x ⁄ 0.75; Olympus, Amsterdam, The Netherlands), Raman
spectra were obtained using a System 1000 Raman microspec-
trometer (Renishaw, Wotton-under-Edge, UK). Ten spectra,
obtained at randomly chosen positions within each smear,
were measured using c. 100-mW laser light (830 nm) and a
signal collection time of 30 s ⁄ spectrum.
Statistical analysis
All spectral analyses were performed as described previously
[30]. Brieﬂy, the ﬁrst derivatives of the spectral range from 400
to 1800 cm)1 were used to minimise the inﬂuence of back-
ground signal caused by slight sample ﬂuorescence. The ten
spectra collected from each smear were averaged, after which
the amount of data was reduced using principal component
analysis (PCA), performed with the PLS toolbox (Eigenvector
Research Inc., Manson, WA, USA) for Matlab software (Math-
works Inc., Natick, MA, USA). These PCA scores were used for
hierarchical cluster analysis (SPSS software; SPSS Inc., Chicago,
IL, USA) to generate a dendrogram. Based on the major clusters
found in the dendrogram, six linear discriminant analysis
models (LDA) were calculated to construct an identiﬁcation
scheme. For LDA, only PCA scores accounting for > 1% of the
variance in the data set were retained. A two-sided t-test was
used to individually select those PCA scores that showed the
highest signiﬁcance in discriminating the different microbial
groups presented. The number of PCA scores used as input for
an LDA model was kept at least two-fold less than the number
of spectra in the smallest model group to prevent overﬁtting in
the LDA model. The prediction accuracy of this model was
tested using a ‘leave-one-strain-out’ method; that is, the spectra
of all but one strain were used to generate the LDA model [30].
By repeating this procedure, and leaving the spectrum of each
strain out in turn, information was obtained on the accuracy
and reproducibility of the identiﬁcation scheme, i.e., whether
there was enough discriminating information in the Raman
spectra to identify spectra of unknown samples correctly.
Patient sample collection
During 11 weeks in 2001, all patients from the surgical ICU or
from the general surgical ward with primary, secondary or
tertiary peritonitis were included prospectively. In total, 88
peritoneal specimens were obtained: 55 from 20 ICU patients;
22 from 17 patients hospitalised on general surgical wards; and
11 from eight patients with an infection following continuous
ambulatory peritoneal dialysis (CAPD). Specimens from peri-
toneal ﬂuid or from an intra-abdominal abscess were obtained
during a laparotomy. Specimens from CAPD ﬂuid were
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obtained directly from the CAPD catheter. Upon arrival in the
microbiology laboratory, each specimen was divided into two,
with one part used for conventional microbiological identiﬁ-
cation (the reference method), and the other for identiﬁcation
by Raman microspectroscopy.
Conventional microbiological identiﬁcation of isolates from
patients
For conventional isolation and identiﬁcation of yeasts, samples
were cultured on CHROMagar Candida medium (Becton
Dickinson). After incubation at 30C for 48 h, a presumptive
identiﬁcation was made, based on distinctive coloured colon-
ies. A deﬁnitive identiﬁcation was then obtained using the
Vitek 2 system (bioMe´rieux, Lyon, France), with a total turn-
around time of 48–96 h.
Raman measurements and identiﬁcation of isolates from
patients
Patient samples were cultured under identical conditions to
the database strains (see above). If positive for yeasts, several
well-isolated colonies from the overnight cultures were
smeared onto a CaF2 substrate. The smears were dried in a
desiccator over drying beads for at least 25 min before Raman
measurements were taken.
RESULTS
Representative Raman spectra acquired from
database Candida strains are shown in Fig. 1.
Close inspection of the spectra revealed that there
were spectral differences characteristic of the
various species. These spectra were subjected to
multivariate analysis to calculate six linear discri-
minant models. Fig. 2 shows the schematic rep-
resentation of this sequential identiﬁcation model.
The strength of this model based on the training
set was evaluated using the ‘leave-one-strain-out’
method. The prediction accuracy of this model
was 87%.
Spectra obtained with patient specimens were
analysed with this species identiﬁcation scheme.
In total, 31 (35%) of 88 specimens were positive
for Candida spp., comprising 30 (55%) of the
specimens from ICU patients and one (5%) of the
specimens from general surgical ward patients.
None of the 11 specimens obtained from a CAPD
catheter was positive for Candida spp. Of the 31
positive specimens, isolates from 29 specimens
were available for further study. Isolates from two
specimens, one identiﬁed by Raman spectroscopy
and one by conventional culture, failed to grow
on further subculture.
Conventional and Raman identiﬁcation of the
29 Candida-positive specimens is summarised in
Table 1. Single Candida spp. were isolated by
conventional culture from 20 specimens, while
nine specimens contained mixed Candida spp. The
Raman species identiﬁcation was obtained by
presenting the spectra to models 1–6 of the
database sequential identiﬁcation scheme
(Fig. 2). There was a difference between the
microbiological and Raman identiﬁcation out-
come in three cases. One C. albicans isolate was
identiﬁed by the Raman technique as Candida
tropicalis, and another as Candida dubliniensis
(Fig. 2: model 2). One mixed culture containing
C. albicans and Candida glabrata was misidentiﬁed
Fig. 1. Representative Raman spectra of ten Candida spp.
used to establish the Candida database in this study. The
shaded areas highlight some characteristic differences
between the species (a.u. = arbitrary units).
Fig. 2. Schematic representation of the sequential species
identiﬁcation procedure, based on the Candida database
LDA model 1–6. Spectra of trial specimens to be identiﬁed
are predicted by using model 1, followed by the next
projections.
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as C. tropicalis. Of the other eight mixed cultures
containing C. albicans and C. glabrata, only
C. albicans (n = 6) or C. glabrata (n = 2) were
identiﬁed by Raman spectroscopy. Taking con-
ventional microbiological identiﬁcation as the
reference method, the accuracy of the Raman
identiﬁcation scheme was 90%.
DISCUSSION
The incidence of nosocomial invasive candidiasis
has risen during the past decades, with a shift
towards the selection of less susceptible Candida
spp. Indeed, in the USA SCOPE survey of
nosocomial Candida bloodstream infections, 50%
of Candida isolates were non-albicans spp. [31].
Awareness, especially in intensive care practice,
of the growing impact of invasive candidiasis is
the ﬁrst step towards rapid identiﬁcation and
diagnosis. However, the increasing incidence of
less susceptible non-albicans spp. has created a
need for rapid and accurate identiﬁcation of
clinically signiﬁcant yeast isolates to enable
prompt initiation of appropriate antifungal ther-
apy. The adequacy of the initial, empirical treat-
ment has proven to be of paramount signiﬁcance
in terms of morbidity and mortality in critically ill
patients with an invasive Candida infection [32].
Clinical microbiologists face an important chal-
lenge in selecting a system for yeast identiﬁcation
that is both rapid and accurate (high speciﬁcity
and sensitivity). No method available currently
meets these criteria fully. Conventional microbio-
logical identiﬁcation is based on an extensive
series of biochemical assays, following an obliga-
tory culture period sufﬁcient to obtain a biomass
of 106)108 cells [33]. This standard identiﬁcation
method is time-consuming, with an unavoidable
turn-around time of 48–96 h. Numerous methods
have been developed with the aim of facilitating
rapid same-day yeast identiﬁcation, but most of
these systems are designed only to discriminate
between two common species or to conﬁrm a
presumptive identiﬁcation [28,34]. A second iden-
tiﬁcation system, such as commercially available
yeast identiﬁcation panels, is often needed for a
deﬁnitive identiﬁcation [35,36]. Consequently, up
to 4 days may be required before a deﬁnitive
report reaches the clinician. In addition, the
reported accuracies of commercial yeast identiﬁ-
cation systems vary from 60% to 99% [28,37].
Therefore, a need still remains for rapid and
accurate multi-species identiﬁcation of signiﬁcant
yeast isolates.
The present study investigated the suitability of
confocal Raman microspectroscopy for the rapid
identiﬁcation of Candida spp., since Raman spec-
tra can be obtained directly from microcolonies on
a solid culture medium after culture for only 6 h.
Following the development of a new, rapid
method for the identiﬁcation of clinically relevant
microorganisms [29], the same method was eval-
uated for the identiﬁcation of Candida spp. with 42
reference strains [30]. A high degree of accuracy
of 97–100% was obtained.
In the present clinical study, the prediction
accuracy of the Raman identiﬁcation method was
90%. One C. albicans isolate was identiﬁed by the
Raman technique as C. dubliniensis [38], which
shares many phenotypic properties with C. albi-
cans, and is often misidentiﬁed as C. albicans in the
microbiology laboratory [28]. However, because
of possible resistance of C. dubliniensis to azole
antifungal agents, it is of great importance to
differentiate the two species. Easy-to-perform
selective isolation procedures for these closely
related species do not exist. Marot-Leblond et al.
[39] have described an anti-C. albicans cell-wall
surface-speciﬁc monoclonal antibody that might
be a candidate for the differentiation of C. albicans
from C. dubliniensis. Tintelnot et al. [27] evaluated
discriminatory phenotypic markers for C. dublini-
ensis, but concluded that only Fourier transform
infrared spectroscopy combined with hierarchical
clustering was as reliable as genotyping for
discriminating the two species. Future Raman
Table 1. Comparison of the results
obtained by conventional microbio-
logical identiﬁcation and Raman
spectroscopy of the Candida strains




C. albicans C. glabrata C. inconspicua C. tropicalis C. dubliniensis Total
C. albicans 13 1 1 15
C. albicans ⁄ glabrata 6 2 1 9
C. glabrata 2 2
C. inconspicua 2 2
C. tropicalis 1 1
Total 19 4 2 3 1 29
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studies with C. albicans and C. dubliniensis isolates
may reveal the accuracy of the method in dis-
criminating these two related species.
For eight mixed cultures containing C. albicans
and C. glabrata, as identiﬁed by culture, only one
of these species was predicted by Raman spectr-
oscopy after incubation on Sabouraud medium,
presumably because a mixed culture was not
detected on this medium and the spectrum of
only one Candida sp. was measured. This was not
counted as a misidentiﬁcation, although this
inﬂuences the prediction accuracy, as it was
believed that this was not caused by the intrinsic
identiﬁcation capabilities of Raman spectroscopy.
Chromogenic media are often used for the recog-
nition and presumptive identiﬁcation of mixed
yeast cultures, and Raman spectra have been
measured from CHROMagar medium isolates
after only one overnight passage (personal
unpublished data). Further studies are required
to measure Raman spectra directly from isolates
cultured on CHROMagar medium, followed by
extended incubation to facilitate the recognition of
mixed cultures. Mixed Candida infections are
uncommon, but not rare, ranging from 9% to
38% of Candida infections [12,15,40]. At present,
use of chromogenic media is the only method that
demonstrates improved detection of yeasts in
mixed cultures over traditional media, although
only presumptive identiﬁcations are obtained.
In the present study, Raman spectra were
measured from smears after overnight culture,
which is practical in a clinical setting, compared
to the microcolonies obtained after growth for 6 h
which were used in the pre-clinical trial [30].
Raman measurements from smears are easier and
more rapid to perform, but are not as homogen-
eous as those obtained with microcolonies. In
total, Raman spectra were measured from 29
overnight cultures, resulting in a turn-around
time of £ 1 day, instead of the period of 3–4 days
required for conventional identiﬁcation. Unfortu-
nately, a dedicated Raman spectrometer or uni-
versal spectral databases are not yet available
commercially. A Raman spectrometer coupled to
a microscope is most practical for studies such as
those described in the present report, and this
combination is available from several commercial
suppliers.
In conclusion, Raman spectroscopy appears to
offer an accurate and rapid alternative for the
identiﬁcation of Candida spp. in ICU patients with
peritonitis. Further investigations should aim to
optimise the technique for improved detection of
mixed Candida cultures and to evaluate the impact
of this novel identiﬁcation method on clinical
practice and patient outcome in a prospective
clinical trial.
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